Necrotizing Pneumonia in an Elderly Patient With Chronic Obstructive Pulmonary Disease (COPD): A Case Report

Necrotizing pneumonia (NP) is a severe complication of bacterial pneumonia, characterized by progressive lung necrosis and cavitation. Although advances in imaging and supportive care have improved outcomes, NP remains difficult to manage due to poor antibiotic penetration, frequent polymicrobial infection, and the lack of standardized treatment protocols. An 85-year-old man with chronic obstructive pulmonary disease (COPD) (Global Initiative for Obstructive Lung Disease (GOLD) group C) and a 40-pack-year former smoking history, managed with long-acting beta-agonist/long-acting muscarinic antagonist (LABA/LAMA), was admitted with acute dyspnea and productive cough. Imaging showed left-sided pneumonia, and methicillin-sensitive <i>Staphylococcus aureus</i> (MSSA) was isolated. Amoxicillin-clavulanate led to transient improvement, but recurrent fever, worsening hypoxemia, and new cavitary lesions developed. Antimicrobial therapy was broadened to piperacillin-tazobactam, vancomycin, and voriconazole, without clinical stabilization. After empiric meropenem, the patient improved, completed 21 days of treatment, and fully recovered. However, without microbiologic confirmation, a direct causal link to meropenem cannot be established. This case highlights the diagnostic and therapeutic challenges of necrotizing pneumonia in elderly COPD patients, particularly when differentiation between progression, relapse, or superinfection is hampered by inconclusive microbiological findings. Although clinical improvement followed escalation to meropenem, the evidence does not permit attribution of recovery solely to this intervention. These findings reinforce the need for frequent reassessment, individualized treatment strategies, and caution in generalizing therapeutic recommendations from individual case reports. Early identification of necrotizing complications and timely modification of antimicrobial therapy are critical. Broad-spectrum antibiotics, including carbapenems, should be reserved for cases with compelling clinical or microbiologic evidence of multidrug resistance, rather than being used routinely based on isolated case experiences.